Loading…

Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment...

Full description

Saved in:
Bibliographic Details
Published in:Clinical practice and epidemiology in mental health 2021, Vol.17 (1), p.307-314
Main Authors: Giesinger, Johannes M, La Nasa, Giorgio, Sparano, Francesco, Angermeyer, Matthias, Morelli, Emanuela, Mulas, Olga, Efficace, Fabio, Caocci, Giovanni
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73
cites cdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73
container_end_page 314
container_issue 1
container_start_page 307
container_title Clinical practice and epidemiology in mental health
container_volume 17
creator Giesinger, Johannes M
La Nasa, Giorgio
Sparano, Francesco
Angermeyer, Matthias
Morelli, Emanuela
Mulas, Olga
Efficace, Fabio
Caocci, Giovanni
description Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.
doi_str_mv 10.2174/1745017902117010307
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2653268042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</originalsourceid><addsrcrecordid>eNptUUtP3DAQtipQodv-gkrIRy5p7fiV5YCEVlCQtuJRerYce9w1cuJtnAWlB357vYIiKnEYzeibmW8eH0KfKflSU8W_FhOEqjmpKVWEEkbUO7S_RastvPMq3kMfcr4jhDW8Zu_RHhOcc0WaffR4DiaOq-oGohnB4euNiWGccPJ4GTzgk5wh5w76EYceX5kxlDDjhzCu8PcJYnJTXkeTx2Dxj6l3Q-ogH-HT--Cgt4B9AfCN6V3qwp_Cv4ihD9ZEfDsEE_NHtOuLg0_PfoZ-np3eLs6r5eW3i8XJsrKsJqpSjVDOk1Y6wlpWLnWg5gW0CqgAJ4lriZBESiG9cb6RVkjua8pcK-fcKDZDx0-8603bgbPliMFEvR5CZ4ZJJxP0_5k-rPSvdK-beSO44oXg8JlgSL83kEfdhWwhRtND2mRdS8Fq2ZDy3xliT6V2SDkP4F_GUKK3yuk3lCtdB683fOn5JxX7C0hNlgk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2653268042</pqid></control><display><type>article</type><title>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</title><source>Bentham Science Publishers OA</source><source>PubMed Central</source><creator>Giesinger, Johannes M ; La Nasa, Giorgio ; Sparano, Francesco ; Angermeyer, Matthias ; Morelli, Emanuela ; Mulas, Olga ; Efficace, Fabio ; Caocci, Giovanni</creator><creatorcontrib>Giesinger, Johannes M ; La Nasa, Giorgio ; Sparano, Francesco ; Angermeyer, Matthias ; Morelli, Emanuela ; Mulas, Olga ; Efficace, Fabio ; Caocci, Giovanni</creatorcontrib><description>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.</description><identifier>ISSN: 1745-0179</identifier><identifier>EISSN: 1745-0179</identifier><identifier>DOI: 10.2174/1745017902117010307</identifier><identifier>PMID: 35444708</identifier><language>eng</language><publisher>United Arab Emirates: Bentham Science Publishers</publisher><subject>Clinical Practice Epidemiology in Mental Health</subject><ispartof>Clinical practice and epidemiology in mental health, 2021, Vol.17 (1), p.307-314</ispartof><rights>2021 Giesinger et al.</rights><rights>2021 Giesinger . 2021 Giesinger</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</citedby><cites>FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985474/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985474/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3740,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35444708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giesinger, Johannes M</creatorcontrib><creatorcontrib>La Nasa, Giorgio</creatorcontrib><creatorcontrib>Sparano, Francesco</creatorcontrib><creatorcontrib>Angermeyer, Matthias</creatorcontrib><creatorcontrib>Morelli, Emanuela</creatorcontrib><creatorcontrib>Mulas, Olga</creatorcontrib><creatorcontrib>Efficace, Fabio</creatorcontrib><creatorcontrib>Caocci, Giovanni</creatorcontrib><title>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</title><title>Clinical practice and epidemiology in mental health</title><addtitle>Clin Pract Epidemiol Ment Health</addtitle><description>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.</description><subject>Clinical Practice Epidemiology in Mental Health</subject><issn>1745-0179</issn><issn>1745-0179</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNptUUtP3DAQtipQodv-gkrIRy5p7fiV5YCEVlCQtuJRerYce9w1cuJtnAWlB357vYIiKnEYzeibmW8eH0KfKflSU8W_FhOEqjmpKVWEEkbUO7S_RastvPMq3kMfcr4jhDW8Zu_RHhOcc0WaffR4DiaOq-oGohnB4euNiWGccPJ4GTzgk5wh5w76EYceX5kxlDDjhzCu8PcJYnJTXkeTx2Dxj6l3Q-ogH-HT--Cgt4B9AfCN6V3qwp_Cv4ihD9ZEfDsEE_NHtOuLg0_PfoZ-np3eLs6r5eW3i8XJsrKsJqpSjVDOk1Y6wlpWLnWg5gW0CqgAJ4lriZBESiG9cb6RVkjua8pcK-fcKDZDx0-8603bgbPliMFEvR5CZ4ZJJxP0_5k-rPSvdK-beSO44oXg8JlgSL83kEfdhWwhRtND2mRdS8Fq2ZDy3xliT6V2SDkP4F_GUKK3yuk3lCtdB683fOn5JxX7C0hNlgk</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Giesinger, Johannes M</creator><creator>La Nasa, Giorgio</creator><creator>Sparano, Francesco</creator><creator>Angermeyer, Matthias</creator><creator>Morelli, Emanuela</creator><creator>Mulas, Olga</creator><creator>Efficace, Fabio</creator><creator>Caocci, Giovanni</creator><general>Bentham Science Publishers</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2021</creationdate><title>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</title><author>Giesinger, Johannes M ; La Nasa, Giorgio ; Sparano, Francesco ; Angermeyer, Matthias ; Morelli, Emanuela ; Mulas, Olga ; Efficace, Fabio ; Caocci, Giovanni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Practice Epidemiology in Mental Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giesinger, Johannes M</creatorcontrib><creatorcontrib>La Nasa, Giorgio</creatorcontrib><creatorcontrib>Sparano, Francesco</creatorcontrib><creatorcontrib>Angermeyer, Matthias</creatorcontrib><creatorcontrib>Morelli, Emanuela</creatorcontrib><creatorcontrib>Mulas, Olga</creatorcontrib><creatorcontrib>Efficace, Fabio</creatorcontrib><creatorcontrib>Caocci, Giovanni</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical practice and epidemiology in mental health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giesinger, Johannes M</au><au>La Nasa, Giorgio</au><au>Sparano, Francesco</au><au>Angermeyer, Matthias</au><au>Morelli, Emanuela</au><au>Mulas, Olga</au><au>Efficace, Fabio</au><au>Caocci, Giovanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials</atitle><jtitle>Clinical practice and epidemiology in mental health</jtitle><addtitle>Clin Pract Epidemiol Ment Health</addtitle><date>2021</date><risdate>2021</risdate><volume>17</volume><issue>1</issue><spage>307</spage><epage>314</epage><pages>307-314</pages><issn>1745-0179</issn><eissn>1745-0179</eissn><abstract>Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia with a variable risk of progression to acute myeloid leukemia. The main goal of therapy for the large majority of patients is to improve health-related quality of life (HRQoL). Its rigorous assessment is now recommended in international MDS guidelines. Our review provides an overview of HRQoL results from randomized controlled trials (RCTs) in MDS patients. The literature search undertaken in PubMed identified 10 RCTs with HRQoL endpoints (all secondary) published between August 2008 and September 2020. These RCTs have helped to better understand the impact of therapies from the patient perspective and have generated valuable information that can be used to further support clinical decisions. However, the number of RCTs in MDS patients, including HRQoL endpoints, is still low. Given the importance of symptom relief and HRQoL improvement in the treatment of MDS patients, the assessment of the patient perspective in future RCTs is highly recommended to keep expanding the knowledge of the impact of new MDS therapies.</abstract><cop>United Arab Emirates</cop><pub>Bentham Science Publishers</pub><pmid>35444708</pmid><doi>10.2174/1745017902117010307</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1745-0179
ispartof Clinical practice and epidemiology in mental health, 2021, Vol.17 (1), p.307-314
issn 1745-0179
1745-0179
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985474
source Bentham Science Publishers OA; PubMed Central
subjects Clinical Practice Epidemiology in Mental Health
title Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A49%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health-Related%20Quality%20of%20Life%20Assessment%20in%20Patients%20with%20Myelodysplastic%20Syndromes:%20Evidence%20from%20Randomized%20Clinical%20Trials&rft.jtitle=Clinical%20practice%20and%20epidemiology%20in%20mental%20health&rft.au=Giesinger,%20Johannes%20M&rft.date=2021&rft.volume=17&rft.issue=1&rft.spage=307&rft.epage=314&rft.pages=307-314&rft.issn=1745-0179&rft.eissn=1745-0179&rft_id=info:doi/10.2174/1745017902117010307&rft_dat=%3Cproquest_pubme%3E2653268042%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3207-7857df0b6d03b3030de79785c7e15ed60db05606656fadf86c564f213db694a73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2653268042&rft_id=info:pmid/35444708&rfr_iscdi=true